Fiasp®▼ is a new formulation of insulin aspart (that incorporates nicotinamide and L-arginine hydrochloride). It has been described as an ‘ultra fast acting insulin’. The addition of another insulin aspart product to the two already available has the potential to create further confusion in the prescribing, dispensing, and administration of these products. This review aims to summarise safety concerns that should be considered.
The UKMI product safety assessment group would appreciate your views on the usefulness of this assessment. We have devised a short survey which we would appreciate you completing, it should take approximately 10 minutes to complete. Click here – https://www.surveymonkey.com/r/UKMiProductSafetyAssessments – to complete the survey.